Nicholas S. Caron

Vancouver, BC V6T1Z3, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Molecular and imaging biomarker responses to brain mutant HTT lowering in a mouse model of Huntington disease.

Molecular and imaging biomarker responses to brain mutant HTT lowering in a mouse model of Huntington disease.

Journal: Molecular therapy. Nucleic acids

Published: May 06, 2025

Challenges and advances for huntingtin detection in cerebrospinal fluid: in support of relative quantification.

Challenges and advances for huntingtin detection in cerebrospinal fluid: in support of relative quantification.

Journal: Biomarker research

Published: December 09, 2024

Challenges and advances for huntingtin detection in cerebrospinal fluid: in support of relative quantification.

Challenges and advances for huntingtin detection in cerebrospinal fluid: in support of relative quantification.

Journal: bioRxiv : the preprint server for biology

Published: October 10, 2024

CAG-targeted brain-permeable therapy tested in biallelic humanized polyQ mouse models.

CAG-targeted brain-permeable therapy tested in biallelic humanized polyQ mouse models.

Journal: Molecular therapy. Nucleic acids

Published: July 19, 2024

Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.

Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.

Journal: Translational neurodegeneration

Published: May 06, 2024

Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington's disease models.

Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington's disease models.

Journal: Brain : a journal of neurology

Published: December 07, 2023

Limitations of Dual-Single Guide RNA CRISPR Strategies for the Treatment of Central Nervous System Genetic Disorders.

Limitations of Dual-Single Guide RNA CRISPR Strategies for the Treatment of Central Nervous System Genetic Disorders.

Journal: Human gene therapy

Published: September 02, 2023

Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease.

Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: August 13, 2023

Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks.

Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: March 20, 2023

Allele-specific quantitation of ATXN3 and HTT transcripts in polyQ disease models.

Allele-specific quantitation of ATXN3 and HTT transcripts in polyQ disease models.

Journal: BMC biology

Published: September 06, 2022

Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity.

Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity.

Journal: Brain communications

Published: May 19, 2022

Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice.

Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice.

Journal: Neurobiology of disease

Published: September 16, 2021

Showing 1-12 of 37

Last Updated: 09/26/2026